INS and obesity due to melanocortin 4 receptor deficiency: Studies show that paclitaxel combined with weight loss management (e.g., intermittent energy restriction and administration of low-fat diets) can reverse the obesity-induced abnormal elevation of serum insulin, leptin, and inflammatory factors, and reduce tumor incidence and weight, thereby reversing the cancer-promoting effect of obesity in mouse EC models [146].